Zanaflex Capsule
Product Images NDC 70515-604

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Zanaflex (NDC 70515-604). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Covis Pharma Us, Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (Zan01 0001 01)

Chemical structure of tizanidine hydrochloride, the active ingredient in Zanaflex. The structure shows a chlorinated aromatic ring fused with a thiazole ring and an attached imidazoline moiety, representing the molecular components of this oral capsule drug.*

FDA Label Image

Figure 1 (Zan01 0001 02)

A plasma concentration-time graph showing tizanidine levels (ng/mL) over 24 hours after dosing. It compares four groups: 2 x 4 mg tizanidine tablets with food, without food; and 2 x 4 mg tizanidine capsules with food, without food. The chart illustrates differences in drug plasma concentration after oral administration under fed and fasted conditions.*

FDA Label Image

Figure 2 (Zan01 0001 03)

A line graph showing improvement in Ashworth Score over 6 hours post-dose for 16 mg tizanidine, 8 mg tizanidine, and placebo groups. The y-axis represents improvement in Ashworth Score, and the x-axis shows hours post-dose from 0 to 6. Data points with error bars indicate measurements at various time intervals for each group.*

FDA Label Image

Figure 3 (Zan01 0001 04)

A line chart depicting improvement in Ashworth Score over three study periods: End of Titration (Study Week 3), End of Maintenance, and Endpoint (Last Observation). It compares tizanidine (mean dose 28.8 mg) and placebo, showing greater improvement with tizanidine at each time point, with error bars indicating variability.*

FDA Label Image

Principal Display Panel (2 mg Capsule Bottle)

Zanaflex 2 mg capsules packaging label showing tizanidine hydrochloride as the active ingredient. The label states 150 capsules per container, manufactured for Covis Pharma US, Inc, with instructions to refer to the package insert for prescribing details. The label includes a warning that these capsules are not interchangeable with tizanidine tablets or other Zanaflex tablets and advises storage at controlled room temperature with child-resistant packaging.*

FDA Label Image

Principal Display Panel (4 mg Capsule Bottle)

Label for Zanaflex Capsules containing 4 mg of tizanidine hydrochloride. The label indicates a package size of 150 capsules. It includes storage instructions, a warning that the capsules are not interchangeable with tizanidine tablets or Zanaflex tablets, and manufacturer information for Covis Pharma, Switzerland. The label also displays the NDC number 70515-604-15.*

FDA Label Image

Principal Display Panel (6 mg Capsule Bottle)

Zanaflex Capsules 6 mg label for tizanidine hydrochloride oral capsules, supplied in a package of 150 capsules. The label is issued by Covis Pharma US, Inc. It includes dosing information, storage instructions, and a warning that these capsules are not interchangeable with tizanidine tablets or Zanaflex tablets. The label features a barcode, lot number, expiration date, and a tamper-evident container notice.*

FDA Label Image

Principal Display Panel (4 mg Tablet Bottle)

Label for Zanaflex 4 mg capsules, containing tizanidine hydrochloride. The label states a package size of 150 tablets and includes labeling information such as the NDC 70515-594-15, manufacturer Covis Pharma US, Inc., and a warning that Zanaflex tablets are not interchangeable with Zanaflex capsules. It also provides storage instructions, prescription information, and a child-resistant closure notice.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.